Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis

NCT06104683 is registered in ClinicalTrials.gov with Loxo Oncology, Inc. as lead sponsor.

NCT NCT06104683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06104683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis
Lead sponsor
Loxo Oncology, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
May 1, 2024
Completion date
February 13, 2026
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing multiple sclerosis